Jones Trading Starts Alto Neuroscience (ANRO) at Buy

Jones Trading analyst Justin Walsh initiates coverage on Alto Neuroscience (NYSE: ANRO) with a Buy rating and a price target of $18.00.

The analyst comments "We are initiating coverage of Alto Neuroscience (ANRO) with a Buy Rating and $18 price target. Alto is a biopharmaceutical company developing therapies for the treatment of central nervous system (CNS) diseases, leveraging their biomarker platform for improved patient identification and selection. The company has five clinical stage assets which are being developed to treat major depressive disorder (MDD), bipolar depression, and/or cognitive impairment in schizophrenia."

For an analyst ratings summary and ratings history on Alto Neuroscience click here. For more ratings news on Alto Neuroscience click here.

Shares of Alto Neuroscience closed at $3.83 yesterday.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• HSBC Downgrades HK Electric (2638:HK) (HKCVF) to Hold
• ​Trump said he was unaware of his earnings from crypto